Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): a phase III, randomized, double-blind, placebo-controlled study

PURPOSE: The Chinese bridging study PUFFIN (NCT02896855) aimed to assess consistency of efficacy with CLEOPATRA (NCT00567190), investigating pertuzumab with trastuzumab and docetaxel versus placebo, trastuzumab, and docetaxel in patients with previously untreated HER2-positive locally recurrent or m...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Binghe, Li, Wei, Zhang, Qingyuan, Shao, Zhimin, Li, Qiao, Wang, Xiaojia, Li, Huiping, Sun, Tao, Yin, Yongmei, Zheng, Hong, Feng, Jifeng, Zhang, Hong, Lei, Guiyuan, Restuccia, Eleonora
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2020
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7320929/
https://www.ncbi.nlm.nih.gov/pubmed/32564260
http://dx.doi.org/10.1007/s10549-020-05728-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7320929/
https://www.ncbi.nlm.nih.gov/pubmed/32564260
http://dx.doi.org/10.1007/s10549-020-05728-w

Ejemplares similares